MIRA INFORM REPORT
|
Report Date : |
23.09.2013 |
IDENTIFICATION DETAILS
|
Name : |
PHARMACOSMOS A/S |
|
|
|
|
Registered Office : |
Roervangsvej 30, Holbæk, 4300 |
|
|
|
|
Country : |
Denmark |
|
|
|
|
Financials (as on) : |
30.04.2012 |
|
|
|
|
Date of Incorporation : |
Not Available |
|
|
|
|
Com. Reg. No.: |
15517085 |
|
|
|
|
Legal Form : |
Private Subsidiary |
|
|
|
|
Line of Business : |
Subject develops and markets medicines for the treatment of iron
deficiency |
|
|
|
|
No. of Employees : |
60 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
Slow but correct |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
Denmark |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
DENMARK - ECONOMIC OVERVIEW
This thoroughly modern
market economy features a high-tech agricultural sector, state-of-the-art
industry with world-leading firms in pharmaceuticals, maritime shipping and
renewable energy, and a high dependence on foreign trade. Denmark is a member
of the European Union (EU); Danish legislation and regulations conform to EU
standards on almost all issues. Danes enjoy a high standard of living and the
Danish economy is characterized by extensive government welfare measures and an
equitable distribution of income. Denmark is a net exporter of food and energy
and enjoys a comfortable balance of payments surplus but depends on imports of
raw materials for the manufacturing sector. Within the EU, Denmark is among the
strongest supporters of trade liberalization. After a long consumption-driven
upswing, Denmark's economy began slowing in 2007 with the end of a housing
boom. Housing prices dropped markedly in 2008-09 and, following a short respite
in 2010, has since continued to decline. The global financial crisis has
exacerbated this cyclical slowdown through increased borrowing costs and lower
export demand, consumer confidence, and investment. The global financial crisis
cut Danish real GDP in 2008-09. Denmark made a modest recovery in 2010 with
real GDP growth of 1.3%, in part because of increased government spending;
however, the country experienced a technical recession in late 2010-early 2011.
Historically low levels of unemployment rose sharply with the recession and
have remained at about 6% in 2010-12, based on the national measure, about
two-thirds average EU unemployment. An impending decline in the ratio of
workers to retirees will be a major long-term issue. Denmark maintained a
healthy budget surplus for many years up to 2008, but the budget balance swung
into deficit in 2009. In spite of the deficits, the new coalition government
delivered a modest stimulus to the economy in 2012. Nonetheless, Denmark's
fiscal position remains among the strongest in the EU with public debt at about
45% of GDP in 2012. Despite previously meeting the criteria to join the
European Economic and Monetary Union (EMU), so far Denmark has decided not to
join, although the Danish krone remains pegged to the euro
|
Source
: CIA |
Company
name and address
|
Pharmacosmos A/S |
|
|
|
||||||||||||||||||||||
|
Employees: |
60 |
|
Company Type: |
Private Subsidiary |
|
Corporate
Family: |
|
|
Ultimate Parent: |
Pharmacosmos Holding A/S |
|
Fiscal Year End:
|
30-Apr-2012 |
|
Reporting
Currency: |
Danish Krone |
|
Annual Sales: |
0.0 |
|
Net Income: |
9.7 |
|
Total Assets: |
118.7 |
|
Business Description |
|
|
Pharmacosmos A/S (Pharmacosmos) is a
pharmaceutical company. The company develops and markets medicines for the treatment
of iron deficiency. Its products includes human iron therapy, veterinary iron
therapy and pharmacosmos dextran. Pharmacosmos operates through its product
brand names such as CosmoFer, Uniferon and Monofer. The company Monofer and
Cosmofer are used to treat iron deficiency anaemia. It Uniferon is a
treatment and prevention of iron deficiency in animals. The company focuses
on improving the options for treatment of iron deficiency anaemia for
patients and healthcare professionals. It develops and market high quality
dextran biopolymers for pharmaceutical and life science products.
Pharmacosmos is headquartered in Holbaek, Denmark. |
|
Industry |
|
|
Industry |
|
|
ANZSIC 2006: |
1841 - Human Pharmaceutical and Medicinal Product
Manufacturing |
|
ISIC Rev 4: |
2100 - Manufacture of pharmaceuticals, medicinal chemical
and botanical products |
|
NACE Rev 2: |
|
|
NAICS 2012: |
|
|
UK SIC 2007: |
|
|
US SIC 1987: |
|
|
|
|
|
|
News |
|
|
Registered No.(DNK)
15517085
1 - Profit & Loss Item Exchange Rate: USD 1 = DKK 5.451689
2 - Balance Sheet Item Exchange Rate: USD 1 = DKK 5.6121
|
||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
Pharmacosmos A/S The Strategic Initiatives report is created using technology to
extract meaningful insights from analyst reports about a company's strategic projects
and investments. More about Strategic
Initiatives
|
|
|
|
|
Christensen added, "Today, we have a
strong base with both human and veterinary products as well as our clinical and
technical dextrans. However, we can see that the market for dextrans, its
derivatives and carbohydrates is growing and thus is extremely
interesting."Dec 17, 2012Pharmacosmos And Copenhagen University Hospital
Collaborate To Improve Stem Cell FreezingCopenhagen University Hospital and
Pharmacosmos A/S, a Danish pharmaceutical company, announced collaboration to improve current stem cell and
tissue freezing methods. The project, Cryodex, has received support from the
Danish National Advanced Technology Foundation.When stem cells and tissue are
frozen, cryoprotectants are used to prevent formation of ice crystals inside
the cells. The most commonly used cryoprotectant, however, is characterized
by a number of side effects. |
|
|
Corporate Family |
Corporate Structure News: |
|
|
|
Company Name |
Company Type |
Location |
Country |
Industry |
Sales |
Employees |
|
|
Pharmacosmos Holding A/S |
Parent |
|
|
|
|
|
|
|
Subsidiary |
Holbæk, 4 |
Denmark |
Pharmaceutical Manufacturing |
0.0 |
60 |
|
|
|
Subsidiary |
Thame |
United Kingdom |
Health and Personal Care Wholesale |
|
|
|
|
|
|
|
|
||||||
|
|
Sweden-Uppsala: Pharmaceutical products |
11-Sep-2013 |
|
|||
|
|
United Kingdom-Runcorn: Pharmaceutical products |
10-Jul-2013 |
|
|||
|
|
Pharmacosmos A/S annual report 2012/2013 |
04-Jul-2013 |
|
|||
|
|
Sweden-Kalmar: Medical equipments, pharmaceuticals and
personal care products |
04-Jul-2013 |
|
|||
|
|
The Top 100 Contract Research Organisations In Western
Europe |
18-Jun-2013 |
|
|||
|
|
Pharmacosmos Holding AS Files Patent Application for a
Stable Iron Oligosaccharide Compound |
13-Mar-2013 |
|
|||
|
|
Denmark - Capitalising on Polish and Russian farmers |
18-Dec-2012 |
|
|||
|
|
Pharmacosmos launches Monofer in Romania |
24-Sep-2012 |
|
|||
Annual Profit & Loss
|
|
30-Apr-2012 |
30-Apr-2011 |
30-Apr-2010 |
|
Period Length |
12 Months |
12 Months |
12 Months |
|
Filed Currency |
DKK |
DKK |
DKK |
|
Exchange Rate (Period
Average) |
5.451689 |
5.610001 |
5.266698 |
|
Consolidated |
No |
No |
No |
|
|
|
|
|
|
Gross Profit |
31.1 |
20.0 |
17.6 |
|
Operating Income |
15.0 |
8.4 |
7.0 |
|
Net Income |
9.7 |
3.3 |
3.2 |
|
|
|
Annual Balance Sheet |
|
Financials in: USD (mil) |
|
|
30-Apr-2012 |
30-Apr-2011 |
30-Apr-2010 |
|
Filed Currency |
DKK |
DKK |
DKK |
|
Exchange Rate |
5.6121 |
5.02665 |
5.59745 |
|
Consolidated |
No |
No |
No |
|
|
|
|
|
|
Total Assets |
118.7 |
121.5 |
116.2 |
|
Provisions |
8.5 |
7.4 |
5.1 |
|
Total Liabilities |
- |
- |
44.7 |
|
Total Equity |
69.6 |
68.1 |
66.4 |
|
|
|
Annual Ratios |
|
|
|
|
30-Apr-2012 |
30-Apr-2011 |
30-Apr-2010 |
|
Period Length |
12 Months |
12 Months |
12 Months |
|
Filed Currency |
- |
- |
- |
|
Exchange Rate |
- |
- |
- |
|
Consolidated |
No |
No |
No |
|
|
|
|
|
|
Current Ratio |
310.75 |
251.65 |
272.08 |
|
Total debt/total equity |
58.63 |
56.04 |
57.17 |
|
Return on average equity |
13.58 |
5.45 |
4.55 |
|
|
|
Annual Growth Rates |
|
|
|
|
30-Apr-2011 |
30-Apr-2010 |
|
Period Length |
12 Months |
12 Months |
|
Filed Currency |
- |
- |
|
Exchange Rate |
- |
- |
|
Consolidated |
No |
No |
|
|
|
|
|
Marginal Contribution Percent Change |
51.43% |
21.10% |
|
Operating Results Percent Change |
73.94% |
26.95% |
|
Profit/Loss for the Year Percent Change |
184.47% |
10.32% |
|
Assets Percent Change |
9.06% |
-6.07% |
|
Provisions Percent Change |
28.73% |
30.10% |
|
Equity Capital Percent Change |
14.08% |
-7.91% |
|
Current Ratio Percent Change |
23.48% |
-7.51% |
|
Debt/Equity Ratio Percent Change |
4.62% |
-1.98% |
|
Retun On Equity Percent Change |
149.17% |
19.78% |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.62.24 |
|
|
1 |
Rs.99.89 |
|
Euro |
1 |
Rs.84.22 |
INFORMATION DETAILS
|
Report Prepared
by : |
PDT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.